

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/673,077
				Filing Date	September 26, 2003
				First Named Inventor	Gunars Valkirs
				Art Unit	1641
				Examiner Name	Lisa V. Cook
Sheet	1	Of	8	Attorney Docket Number	36671-743.502

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US 2002/0052000 A1	05/02/2002	Parthasarathy et al.	
	2.	US 2002/0106708 A1	08/08/2002	Thomas et al.	
	3.	US 2003/0119064 A1	06/26/2003	Valkirs et al.	
	4.	US 2003/0199000 A1	10/23/2003	Valkirs et al.	
	5.	US 2003/0211544 A1	11/13/2003	Buechler et al.	
	6.	US 2003/0219734 A1	11/27/2003	Buechler	
	7.	US 2004/0121343 A1	06/24/2004	Buechler et al.	
	8.	US 2004/0121350 A1	06/24/2004	Anderberg et al.	
	9.	US 2004/0126767 A1	07/01/2004	Anderberg et al.	
	10.	US 2004/0171064 A1	09/02/2004	Dahlen et al.	
	11.	US 2004/0176914 A1	09/09/2004	Buechler et al.	
	12.	US 2004/0203083 A1	10/14/2004	Buechler et al.	
	13.	US 2004/0219509 A1	11/04/2004	Valkirs et al.	
	14.	US 2004/0253637 A1	12/16/2004	Buechler et al.	
	15.	US 2005/0148024 A1	07/07/2005	Buechler	
	16.	US 2005/0164317 A1	07/28/2005	Buechler et al.	
	17.	US 2005/0244902 A1	11/03/2005	Goetze et al.	
	18.	US 2005/0255484 A1	11/17/2005	Valkirs et al.	
	19.	US 2006/0051825 A1	03/09/2006	Buechler et al.	
	20.	US 2006/0105419 A1	05/18/2006	Blankenberg et al.	
	21.	US 2007/0092911 A1	04/26/2007	Buechler et al.	
	22.	US 2007/0196880 A1	08/23/2007	Buechler et al.	
	23.	US 2007/0218498 A1	09/20/2007	Buechler et al.	
	24.	US 2007/0224643 A1	09/27/2007	Mcpherson et al.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/673,077
				Filing Date	September 26, 2003
				First Named Inventor	Gunars Valkirs
				Art Unit	1641
				Examiner Name	Lisa V. Cook
Sheet	2	Of	8	Attorney Docket Number	36671-743.502

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	25.	US 2007/0269836 A1	11/22/2007	Mcpherson	
	26.	US 2008/0045444 A1	02/21/2008	Whittaker	
	27.	US 2008/0118924 A1	05/22/2008	Buechler	
	28.	US 4,900,662	02/13/1990	Shah et al.	
	29.	US 5,028,535	07/02/1991	Buechler et al.	
	30.	US 5,202,234	04/13/1993	Shah et al.	
	31.	US 5,206,140	04/27/1993	Marder et al.	
	32.	US 5,382,515	01/17/1995	Shah et al.	
	33.	US 5,382,522	01/17/1995	Shah et al.	
	34.	US 5,482,935	01/09/1996	Adelman et al.	
	35.	US 5,683,885	11/04/1997	Kieback	
	36.	US 5,795,725	08/18/1998	Buechler et al.	
	37.	US 5,814,462	09/29/1998	Weinberger	
	38.	US 5,843,690	12/01/1998	Gargan	
	39.	US 6,156,521	12/05/2000	Buechler et al.	
	40.	US 6,174,686 B1	01/16/2001	Buechler et al.	
	41.	US 6,309,888 B1	10/30/2001	Holvoet et al.	
	42.	US 6,461,828 B1	10/08/2002	Stanton et al.	
	43.	US 6,495,519 B1	12/17/2002	He et al.	
	44.	US 6,579,687 B1	06/17/2003	Buechler et al.	
	45.	US 6,627,404 B1	09/30/2003	Buechler et al.	
	46.	US 6,939,678 B1	09/06/2005	Buechler et al.	
	47.	US 6,991,907 B1	01/31/2006	Buechler et al.	
	48.	US 7,341,838 B2	03/11/2008	Buechler et al.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/673,077
				Filing Date	September 26, 2003
				First Named Inventor	Gunars Valkirs
				Art Unit	1641
				Examiner Name	Lisa V. Cook
Sheet	3	Of	8	Attorney Docket Number	36671-743.502

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	49.	US 7,358,055 B2	04/15/2008	Valkirs et al.	
	50.	US 7,361,473 B2	04/22/2008	Valkirs et al.	
	51.	US 7,427,490 B2	08/20/2002	Valkirs	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	52.	WO 1998/043630 A1	08/10/1998	Ridker et al.		
	53.	WO 2001/042793 A2	06/14/2001	Hochstrasser et al.		
	54.	WO 2002/083913 A1	10/24/2002	Dahlen et al.		
	55.	WO 2004/058055 A2	07/15/2004	Anderberg et al.		
	56.	WO 2004/094459 A2	11/04/2004	Buechler		
	57.	WO 2004/094460 A2	11/04/2004	Buechler et al.		

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	58.	ANDERSON, L. Candidate-Based Proteomics in the Search for Biomarkers of Cardiovascular Disease. J. Physiol. 563.1; 2004: 23-60.
	59.	BARBER, et al. Hemostatic function and progressing ischemic stroke: D-dimer predicts early clinical progression. Stroke. 2004 Jun;35(6):1421-5. Epub 2004 Apr 8.
	60.	BERENDES, et al. Secretion of brain natriuretic peptide in patients with aneurysmal subarachnoid haemorrhage. Lancet. 1997 Jan 25;349(9047):245-9.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/673,077
				Filing Date	September 26, 2003
				First Named Inventor	Gunars Valkirs
				Art Unit	1641
				Examiner Name	Lisa V. Cook
Sheet	4	Of	8	Attorney Docket Number	36671-743.502

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	61.	BREYER, J. dissenting. Supreme Court of The United States, No. 04-607. Laboratory Coproration of America Holdings, DBA Labcorp, Petitioner v. Metabolite Laboratories, Inc., et al. June 22, 2006 (slip opinion) pages 1-15.
	62.	CARVILLE, et al. Thrombus precursor protein (TpPTM): marker of thrombosis early in the pathogenesis of myocardial infarction. Clin. Chem. 1996;42:1537-1541.
	63.	CASSIN, et al. E' realizzabile una strategia operativa più efficace per la gestione in urgenza con dolore toracico acuto? Ital. Heart Suppl. Feb. 2002;1: 186-201. (In Italian with English abstract)
	64.	CHANG, et al. C-Reactive Protein Binds to Both Oxidized LDL and Apototic Cells Through Recognition of a Common Ligand: Phosphorylcholine of Oxidized Phospholipids.
	65.	CHOUDHRI, et al. Targeted inhibition of intrinsic coagulation limits cerebral injury in stroke without increasing intracerebral hemorrhage. J Exp Med. 1999 Jul 5;190(1):91-9.
	66.	CHRISTENSON, et al. Standardization of cardiac troponin I assays: round Robin of ten candidate reference materials. Clin Chem. 2001 Mar;47(3):431-7.
	67.	CLARK, et al. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett. 1997 Nov 28;238(1-2):53-6.
	68.	COEROLI, et al. Nitric oxide production and perivascular tyrosine nitration following focal ischemia in neonatal rat. J Neurochem. 1998 Jun;70(6):2516-25.
	69.	COSSINS, et al. Enhanced Expression of MMP-7 and MMP-9 in Demyelinating Multiple Sclerosis Lesions. Acta. Neuropathol. 1997;94:590-598.
	70.	EIKELBOOM, et al. C-reactive protein in ischemic stroke and its etiologic subtypes. J Stroke Cerebrovasc Dis. 2003 Mar-Apr;12(2):74-81.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known		
				Application Number	10/673,077	
				Filing Date	September 26, 2003	
				First Named Inventor	Gunars Valkirs	
				Art Unit	1641	
				Examiner Name	Lisa V. Cook	
Sheet	5	Of	8	Attorney Docket Number		36671-743.502

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	71.	FONAROW, et al. Combining Natriuretic Peptides and Necrosis Markers In Determining Prognosis in Heart Failure. Reviews in Cardiovascular Medicine. 2003; 4(4):S20-S28.
	72.	FUKUI, et al. Focal Brain Edema and Natriuretic Peptides in Patients with Subarachnoid Hemorrhage. J. of Clin. Neuroscience. 2004;11(5): 507-511.
	73.	HARRINGTON, J.R. The Role of MCP-1 in Atherosclerosis. Stem Cells. 2000;18: 65-66.
	74.	HATFIELD, et al. CSF neuron-specific enolase as a quantitative marker of neuronal damage in a rat stroke model. Brain Res. 1992 Apr 17;577(2):249-52. (abstract only)
	75.	HEESCHEN, et al. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. The Lancet. 2000;354: 261-272.
	76.	HWANG, et al. Circulating Adhesion Molecules VCAM-1, ICAM-1, and E-selectin in Carotid Atherosclerosis and Incident Coronary heart Disease Cases. Circulation 1997;96:4219-4225.
	77.	INDIK, et al. Detection of pulmonary embolism by D-dimer assay, spiral computed tomography, and magnetic resonance imaging. Prog. Cardiovasc. Dis. 2000; 42: 261-272.
	78.	International Search Report and the Written Opinion of the International Searching Authority dated 07/03/2008 from PCT Application No. US05/38225.
	79.	KANEKO, et al. Measurement of plasma annexin V by ELISA in the early detection of acute myocardial infarction. J. Rheumatol. 1999;26:568-573.
	80.	KLINE, et al. New diagnostic tests for pulmonary embolism. Ann Emerg Med. 2000 Feb;35(2):168-80.
	81.	LESCUYER, et al. Identification of Post-Mortem Cerebral Spinal Fluid Proteins as Potential Biomarkers of Ischemia and Neurodegeneration. Proteomics. 2004;(4): 2234-2241.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1458, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/673,077
				Filing Date	September 26, 2003
				First Named Inventor	Gunars Valkirs
				Art Unit	1641
				Examiner Name	Lisa V. Cook
Sheet	6	Of	8	Attorney Docket Number	36671-743.502

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	82.	LINDON, J. C. Biomarkers: Present concepts and future promise. Preclinica. 2003;1: 221.
	83.	LIP, et al. Von Willebrand Factor and Its Relevance to Cardiovascular Disorders. Br Heart J. 1995;74:580-583.
	84.	MA, et al. RAGE is expressed in pyramidal cells of the hippocampus following moderate hypoxic-ischemic brain injury in rats. Brain Res. 2003 Mar 21;966(2):167-74.
	85.	Management of the patient with stroke. Chapter One - Trends in stroke prevention and management. Available at: http://69.3.158.146/nurse/courses/nurseweek/NW0200/c1/p01.htm
	86.	McGIRT, et al. Serum Von Willebrand Factor, Matrix Metalloproteinase-9 and Vascular Endothelial Growth Factor Levels Predict the Onset of Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage. Neurosurgery. 2002;51(5):1128-1135.
	87.	MULLINS, et al. CT and conventional and diffusion-weighted MR imaging in acute stroke: study in 691 patients at presentation to the emergency department. Radiology. 2002 Aug;224(2):353-60.
	88.	NAKAGAWA, et al. Plasma concentrations of brain natriuretic peptide in patients with acute ischemic stroke. Cerebrovasc Dis. 2005;19(3):157-64.
	89.	NG, et al. Biomedical applications of protein chips. J Cell Mol Med. 2002 Jul-Sep;6(3):329-40.
	90.	Office Action from Japanese Patent Office dated 06/10/2008 for Japanese Application No. JP2003-521366 (in Japanese with English translation).
	91.	ORBE, et al. Independent association of matrix metalloproteinase-10, cardiovascular risk factors and subclinical atherosclerosis. Journal of Thrombosis and Haemostasis 2007;5 (1) , 91-97.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/673,077
				Filing Date	September 26, 2003
				First Named Inventor	Gunars Valkirs
				Art Unit	1641
				Examiner Name	Lisa V. Cook
Sheet	7	Of	8	Attorney Docket Number	36671-743.502

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	92.	RICHARDS, et al. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. Heart. 1999; 81:114-120.
	93.	RUS, et al. Interleukin-6 and Interleukin-8 protein and Gene Expression in Human Arterial Atherosclerotic Wall. Atherosclerosis. 1996;127:263-271.
	94.	SAADY, et al. Left atrial appendage: structure, function, and role in thromboembolism. Heart. 1999 November; 82(5): 547-554.
	95.	SAGNELLA, G. A. Measurement and significance of circulating natriuretic peptides in cardiovascular disease. Clin Sci (Lond). 1998 Nov;95(5):519-29.
	96.	SHIRASAKI, et al. Serum S-100b protein as a biomarker for the assessment of neuroprotectants. Brain Res. 2004 Sep 24;1021(2):159-66.
	97.	SONEL, et al. Prospective study correlating fibrinopeptide A, troponin I, myoglobin, and myosin light chain levels with early and late ischemic events in consecutive patients presenting to the emergency department with chest pain. Circulation. 2000 Sep 5;102(10):1107-13.
	98.	STANEK, et al. Prognostic Evaluation of Neurohumoral Plasma Levels Before and During Beta Blocker Therapy in Advanced Left Ventricular Dysfunction. JACC. 2002;38(2): 436-442.
	99.	TAKEBAYASHI, et al. Association between circulating monocyte chemoattractant protein-1 and urinary albumin excretion in nonobese Type 2 diabetic patients. J Diabetes Complications. 2006 Mar-Apr;20(2):98-104.
	100.	TOMIDA, et al. Plasma concentrations of brain natriuretic peptide in patients with subarachnoid hemorrhage. Stroke. 1998 Aug;29(8):1584-7.
	101.	Tumor necrosis factor ligand superfamily member 12. Human Protein Reference Database. Available at: www.hprd.org/alternate?protein=04074&isoform_id=04074_1&isoform_name=Isoform_1

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/673,077
				Filing Date	September 26, 2003
				First Named Inventor	Gunars Valkirs
				Art Unit	1641
				Examiner Name	Lisa V. Cook
Sheet	8	Of	8	Attorney Docket Number	36671-743.502

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	102.	USHIYAMA, et al. Structural and functional characterization of monomeric soluble P-selectin and comparison with membrane P-selectin. J Biol Chem. 1993 Jul 15;268(20):15229-37.
	103.	VASAN, et al. Plasma Natriuretic Peptides for Community Screening for Left Ventricular Hypertrophy and Systolic Dysfunction. JAMA. 2002;288(10): 1252-1259.
	104.	VASAN, R. S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006 May 16;113(19):2335-62.
	105.	VELIER, et al. Caspase-8 and caspase-3 are expressed by different populations of cortical neurons undergoing delayed cell death after focal stroke in the rat. J Neurosci. 1999 Jul 15;19(14):5932-41.
	106.	YIP, et al. Time course and prognostic value of plasma levels of N-terminal pro-brain natriuretic peptide in patients after ischemic stroke. Circ J. 2006 Apr;70(4):447-52.
	107.	ZHOU, et al. HBO suppresses Nogo-A, Ng-R, or RhoA expression in the cerebral cortex after global ischemia. Biochem Biophys Res Commun. 2003 Sep 19;309(2):368-76.
	108.	ZWEIG, et al. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993 Apr;39(4):561-77.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.